You are here: Industry Insights > hepatitis C

News List

Included in China’s National Essential Drugs List, Can Epclusa Get a Second Wind in China? (2) 1℃
November 21, 2018
I mentioned in previous articles that genotypes of Chinese hepatitis C patients are mainly 1b and 2a/c, with the number of hepatitis C patients of about 26 million in total but treatment rate of less than 0.5%! The market space is huge.
Included in China’s National Essential Drugs List, Can Epclusa Get a Second Wind in China? (1) 1℃
November 20, 2018
The 2018 Edition National Essential Drugs List of China was officially published on October 25, 2018, which attracts extensive attention of the industry.
Brazilian court strips Gilead of its patent for Hepatitis C drug Sovaldi pharmaceutical-technology
September 30, 2018
A judge from the 21st Federalist Court of Brasilia has ruled to invalidate US biopharma company Gilead’s exclusivity patent for Sovaldi (sofosbuvir), which is indicated for Hepatitis C.
Ganovo gets enrolled in basic medical Insurance of Tianjin biospectrum
September 28, 2018
The Pilot Program supports hepatitis C patients get timely access to most innovative treatments and aims to eliminate hepatitis C in China by 2030.
Gilead launches generics of own hepatitis C drugs in US to cut health costs pharmaphorum
September 27, 2018
Gilead is to launch cheaper generic versions of its hepatitis C drugs in the US, responding to calls for lower drug prices because of spiralling healthcare costs.
AbbVie surprised investors with its hepatitis C success. Will it last? biopharmadive
August 13, 2018
By the time AbbVie brought its first drug for hepatitis C to market, in December 2014, it was already too late.
World Hepatitis Day 2018: 89% of people with hepatitis are unaware pharmaceutical-technology
July 31, 2018
The World Hepatitis Alliance’s (WHA) global campaign for World Hepatitis Day 2018 on 28 July and the next three years focuses on ‘finding the mission millions’ with viral hepatitis. It is estimated that only 11% of people with viral hepatitis are aware, m
Direct-Acting Antivirals Effective for Hepatitis C in Seniors drugs
June 26, 2018
For older patients with hepatitis C virus (HCV), direct-acting antiviral (DAA) therapy is effective, according to a study published online May 25 in the Journal of the American Geriatrics Society.
CDA approves Gilead’s chronic hepatitis C virus infection drug biospectrumasia
June 01, 2018
HCV is the fourth-most commonly reported infectious disease in China, with approximately 10 million people infected. HCV genotypes 1, 2, 3 and 6 account for more than 96 percent of all cases.
New hepatitis C combo boasts 97% cure rate for just $300 pharmafile
April 13, 2018
A partnership of the not-for-profit organisation Drugs for Neglected Diseases initiative (DNDi) and Egyptian drug firm Pharco Pharmaceuticals is working to bring a new, effective and affordable combination therapy to patients with hepatitis C (HCV).

Previous page 1 2 3 Next page